Anacor Pharmaceuticals (ANAC) 33.86 $ANAC
Insider Trading Alert - BLUE, ANAC And FRME Traded By Insiders
at The Street - Thu Dec 04, 12:00PM CST
Stocks with insider trader activity include BLUE, ANAC and FRME
BLUE: 91.28 (+5.16), ANAC: 33.86 (-0.82), FRME: 21.77 (-0.32)
Hypersensitivity - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/fbrzhk/hypersensitivity) has announced the addition of the "Hypersensitivity - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypersensitivity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypersensitivity and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypersensitivity - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Anacor Pharmaceuticals - Eisai - F. Hoffmann-La Roche - JW Pharmaceutical For more information visit http://www.researchandmarkets.com/research/fb...ensitivity
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals' Sales Of Kerydin May Be Better Than Expected
Clinically Sound Investor - at Seeking Alpha - Fri Nov 21, 8:42AM CST
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals to Present at the 2014 Credit Suisse Healthcare Conference
Business Wire - Fri Nov 07, 3:36PM CST
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company's President and Chief Executive Officer, will provide a company overview at the 2014 Credit Suisse Healthcare Conference on Thursday, November 13, 2014 at 9:00 a.m. MT in Phoenix, Arizona. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
ANAC: 33.86 (-0.82)
Global Contact Dermatitis Therapeutics Pipeline Review 2014 - Analysis of 4 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/bdskj2/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contact Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - R-Tech Ueno, Ltd. - Marinomed Biotechnologie GmbH - Anacor Pharmaceuticals, Inc. - Celsus Therapeutics Plc Drug Profiles - MRX-6 - RTU-1096 - bordetella pertussis vaccine [BPZE1] - MAM-06301 - AN-3485 - HPT-721 For more information visit http://www.researchandmarkets.com/research/bdskj2/contact
CLTX: 5.24 (-0.06), ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals' (ANAC) CEO Paul Berns on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 10:26PM CST
ANAC: 33.86 (-0.82)
Anacor posts 3Q loss
Automated Insights - Thu Nov 06, 6:33PM CST
PALO ALTO, Calif. (AP) _ Anacor Pharmaceuticals Inc. (ANAC) on Thursday reported a loss of $31.3 million in its third quarter.
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals misses by $0.08, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:19PM CST
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 3:01PM CST
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended September 30, 2014.
ANAC: 33.86 (-0.82)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.65 (+0.05), ACET: 21.02 (-0.07), ANET: 67.95 (+0.05), FNGN: 33.59 (-0.11), CPST: 0.71 (+0.01), AUQ: 3.30 (-0.02), AMRN: 1.08 (+0.04), ED: 64.11 (-0.32), ENV: 47.16 (-0.69), FXCM: 16.50 (+0.08), BCEI: 18.57 (-0.79), GXP: 26.55 (-0.18), EAC: 8.16 (-0.17), DXCM: 53.66 (-0.67), CSC: 61.32 (-1.16), AEL: 27.73 (-0.12), HNSN: 0.66 (unch), CFN: 58.86 (-0.14), ANAC: 33.86 (-0.82), DAR: 17.85 (+0.10), GST: 2.55 (unch), ARC: 9.25 (-0.26), FIVN: 4.21 (-0.17), ELON: 1.73 (+0.04), FSLR: 42.12 (-0.92), EZPW: 11.13 (+0.20), ALIM: 5.49 (-0.02), FWM: 2.83 (-0.12), BRS: 59.37 (-1.74), ECOM: 19.98 (-0.08), FTEK: 3.63 (-0.08), CVT: 27.59 (-0.15), AL: 32.59 (-2.11), BBRG: 12.97 (-0.15), BPZ: 0.24 (unch), ECPG: 40.04 (-0.40), HTGC: 14.44 (-0.42), AIRM: 42.29 (-0.34), BNFT: 23.68 (+0.12), ENOC: 14.72 (-0.11), HPTX: 21.89 (+0.02), AGO: 25.71 (-0.57), FICO: 71.16 (-1.36), FF: 11.89 (-0.49), FI: 15.22 (-0.88), EVC: 7.14 (-0.17), EBS: 26.04 (-0.33), ABCO: 46.02 (+1.45), DIOD: 26.37 (-0.39), DIS: 91.49 (-0.26), EGOV: 17.64 (-0.60), APEI: 34.07 (-0.20), DVA: 73.40 (-1.11), CLVS: 55.15 (+0.32), HCI: 43.14 (+0.01), BRKR: 18.57 (-0.44), HGR: 21.22 (+0.21)
Anacor Pharmaceuticals Announces Third Quarter 2014 Financial Results Conference Call and Webcast
Business Wire - Thu Oct 30, 3:30PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and may be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com where it will be available for three months following the call.
ANAC: 33.86 (-0.82)
Strong On High Relative Volume: Anacor Pharmaceuticals (ANAC)
at The Street - Mon Oct 20, 9:05AM CDT
Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a strong on high relative volume candidate
ANAC: 33.86 (-0.82)
Dupilumab dermatitis trial underway
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:56AM CDT
PRGO: 153.41 (-3.13), VRX: 138.71 (-0.18), ANAC: 33.86 (-0.82), GSK: 42.42 (-0.93), SNY: 45.16 (-1.05), REGN: 416.44 (-7.91)
3 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 13, 6:22AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
IPXL: 31.16 (-0.74), ANAC: 33.86 (-0.82), MSTR: 158.24 (-9.17)
Anacor Pharmaceuticals prices offering of USD75m convertible senior notes
M2 - Fri Oct 10, 6:57AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) said on Thursday that it has priced its offering of USD75m aggregate principal amount of 2.00% convertible senior notes due 2021 in a private placement.
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals, Inc. Announces Pricing of Offering of $75 Million of 2.00% Convertible Senior Notes Due 2021
Business Wire - Thu Oct 09, 6:29PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today the pricing of its offering of $75,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $7,500,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. In addition, certain funds affiliated with Venrock Associates, one of Anacor's affiliates, have agreed to purchase $8.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Venrock Notes" in a concurrent private placement under the Securities Act. The Venrock Notes will be sold at the same price, and will constitute part of the same series, as the Convertible Notes. The offering of the Convertible Notes is expected to close on October 16, 2014, subject to customary closing conditions. The sale of the Venrock Notes is also expected to close on October 16, 2014, subject to the closing of the Convertible Notes offering.
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals, Inc. Announces Proposed Offering of $70 Million of Convertible Senior Notes Due 2021
Business Wire - Wed Oct 08, 3:01PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it intends to offer, subject to market and other considerations, $70,000,000 aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes" in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $7,000,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. In addition, certain funds affiliated with Venrock Associates (the "Venrock Funds" , one of Anacor's affiliates, have indicated an interest in purchasing $12.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Venrock Notes" in a concurrent private placement under the Securities Act. The Venrock Notes are expected to be sold at the same price, and constitute part of the same series, as the Convertible Notes. The Venrock Funds' indication of interest is not a binding agreement or commitment to purchase the Venrock Notes.
ANAC: 33.86 (-0.82)
Insider Trading Alert - NDAQ, ANAC And RNR Traded By Insiders
at The Street - Fri Oct 03, 10:15AM CDT
Stocks with insider trader activity include NDAQ, ANAC and RNR
RNR: 96.64 (-0.77), ANAC: 33.86 (-0.82), NDAQ: 46.11 (-0.86)
Anacor's Kerydin Launched in the US for Onychomycosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:05PM CDT
Anacor Pharmaceuticals, Inc.'s (ANAC) Kerydin has been launched in the U.S. by partner Sandoz Inc., a Novartis company.
ANAC: 33.86 (-0.82), SNY: 45.16 (-1.05), REGN: 416.44 (-7.91), NVS: 93.52 (-0.82)
Anacor Pharmaceuticals unveils antifungal drug KERYDIN (tavaborole) Topical Solution, 5% in the US
M2 - Tue Sep 23, 4:47AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) Monday reported the US launch of its US Food and Drug Administration approved drug KERYDINTM (tavaborole) topical solution, 5%.
ANAC: 33.86 (-0.82)
Insider Trading Alert - BLUE, ANAC And FRME Traded By Insiders
at The Street - Thu Dec 04, 12:00PM CST
Stocks with insider trader activity include BLUE, ANAC and FRME
BLUE: 91.28 (+5.16), ANAC: 33.86 (-0.82), FRME: 21.77 (-0.32)
Hypersensitivity - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/fbrzhk/hypersensitivity) has announced the addition of the "Hypersensitivity - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypersensitivity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypersensitivity and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypersensitivity - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Anacor Pharmaceuticals - Eisai - F. Hoffmann-La Roche - JW Pharmaceutical For more information visit http://www.researchandmarkets.com/research/fb...ensitivity
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals' Sales Of Kerydin May Be Better Than Expected
Clinically Sound Investor - at Seeking Alpha - Fri Nov 21, 8:42AM CST
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals to Present at the 2014 Credit Suisse Healthcare Conference
Business Wire - Fri Nov 07, 3:36PM CST
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that Paul Berns, the company's President and Chief Executive Officer, will provide a company overview at the 2014 Credit Suisse Healthcare Conference on Thursday, November 13, 2014 at 9:00 a.m. MT in Phoenix, Arizona. The event will be webcast live and may be accessed under "Events and Presentations" on the Investors page of Anacor's website at www.anacor.com. A replay will also be available for three months following the presentation.
ANAC: 33.86 (-0.82)
Global Contact Dermatitis Therapeutics Pipeline Review 2014 - Analysis of 4 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/bdskj2/contact) has announced the addition of the "Contact Dermatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contact Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - R-Tech Ueno, Ltd. - Marinomed Biotechnologie GmbH - Anacor Pharmaceuticals, Inc. - Celsus Therapeutics Plc Drug Profiles - MRX-6 - RTU-1096 - bordetella pertussis vaccine [BPZE1] - MAM-06301 - AN-3485 - HPT-721 For more information visit http://www.researchandmarkets.com/research/bdskj2/contact
CLTX: 5.24 (-0.06), ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals' (ANAC) CEO Paul Berns on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 10:26PM CST
ANAC: 33.86 (-0.82)
Anacor posts 3Q loss
Automated Insights - Thu Nov 06, 6:33PM CST
PALO ALTO, Calif. (AP) _ Anacor Pharmaceuticals Inc. (ANAC) on Thursday reported a loss of $31.3 million in its third quarter.
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals misses by $0.08, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:19PM CST
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals Reports Third Quarter 2014 Financial Results
Business Wire - Thu Nov 06, 3:01PM CST
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended September 30, 2014.
ANAC: 33.86 (-0.82)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:35PM CST
BEBE: 2.65 (+0.05), ACET: 21.02 (-0.07), ANET: 67.95 (+0.05), FNGN: 33.59 (-0.11), CPST: 0.71 (+0.01), AUQ: 3.30 (-0.02), AMRN: 1.08 (+0.04), ED: 64.11 (-0.32), ENV: 47.16 (-0.69), FXCM: 16.50 (+0.08), BCEI: 18.57 (-0.79), GXP: 26.55 (-0.18), EAC: 8.16 (-0.17), DXCM: 53.66 (-0.67), CSC: 61.32 (-1.16), AEL: 27.73 (-0.12), HNSN: 0.66 (unch), CFN: 58.86 (-0.14), ANAC: 33.86 (-0.82), DAR: 17.85 (+0.10), GST: 2.55 (unch), ARC: 9.25 (-0.26), FIVN: 4.21 (-0.17), ELON: 1.73 (+0.04), FSLR: 42.12 (-0.92), EZPW: 11.13 (+0.20), ALIM: 5.49 (-0.02), FWM: 2.83 (-0.12), BRS: 59.37 (-1.74), ECOM: 19.98 (-0.08), FTEK: 3.63 (-0.08), CVT: 27.59 (-0.15), AL: 32.59 (-2.11), BBRG: 12.97 (-0.15), BPZ: 0.24 (unch), ECPG: 40.04 (-0.40), HTGC: 14.44 (-0.42), AIRM: 42.29 (-0.34), BNFT: 23.68 (+0.12), ENOC: 14.72 (-0.11), HPTX: 21.89 (+0.02), AGO: 25.71 (-0.57), FICO: 71.16 (-1.36), FF: 11.89 (-0.49), FI: 15.22 (-0.88), EVC: 7.14 (-0.17), EBS: 26.04 (-0.33), ABCO: 46.02 (+1.45), DIOD: 26.37 (-0.39), DIS: 91.49 (-0.26), EGOV: 17.64 (-0.60), APEI: 34.07 (-0.20), DVA: 73.40 (-1.11), CLVS: 55.15 (+0.32), HCI: 43.14 (+0.01), BRKR: 18.57 (-0.44), HGR: 21.22 (+0.21)
Anacor Pharmaceuticals Announces Third Quarter 2014 Financial Results Conference Call and Webcast
Business Wire - Thu Oct 30, 3:30PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) will release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014 at approximately 4:00 p.m. ET / 1:00 p.m. PT. The announcement will be followed by a conference call at 5:00 p.m. ET / 2:00 p.m. PT during which management will discuss the company's financial results and recent developments. The call may be accessed by dialing (877) 291-1367 (domestic) and (914) 495-8534 (international) five minutes prior to the start of the call. The call will also be webcast live and may be accessed on the Events and Presentations page, under Investors, on the company's website at www.anacor.com where it will be available for three months following the call.
ANAC: 33.86 (-0.82)
Strong On High Relative Volume: Anacor Pharmaceuticals (ANAC)
at The Street - Mon Oct 20, 9:05AM CDT
Trade-Ideas LLC identified Anacor Pharmaceuticals (ANAC) as a strong on high relative volume candidate
ANAC: 33.86 (-0.82)
Dupilumab dermatitis trial underway
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:56AM CDT
PRGO: 153.41 (-3.13), VRX: 138.71 (-0.18), ANAC: 33.86 (-0.82), GSK: 42.42 (-0.93), SNY: 45.16 (-1.05), REGN: 416.44 (-7.91)
3 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 13, 6:22AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
IPXL: 31.16 (-0.74), ANAC: 33.86 (-0.82), MSTR: 158.24 (-9.17)
Anacor Pharmaceuticals prices offering of USD75m convertible senior notes
M2 - Fri Oct 10, 6:57AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) said on Thursday that it has priced its offering of USD75m aggregate principal amount of 2.00% convertible senior notes due 2021 in a private placement.
ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals, Inc. Announces Pricing of Offering of $75 Million of 2.00% Convertible Senior Notes Due 2021
Business Wire - Thu Oct 09, 6:29PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today the pricing of its offering of $75,000,000 aggregate principal amount of 2.00% Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $7,500,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. In addition, certain funds affiliated with Venrock Associates, one of Anacor's affiliates, have agreed to purchase $8.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Venrock Notes" in a concurrent private placement under the Securities Act. The Venrock Notes will be sold at the same price, and will constitute part of the same series, as the Convertible Notes. The offering of the Convertible Notes is expected to close on October 16, 2014, subject to customary closing conditions. The sale of the Venrock Notes is also expected to close on October 16, 2014, subject to the closing of the Convertible Notes offering. ANAC: 33.86 (-0.82)
Anacor Pharmaceuticals, Inc. Announces Proposed Offering of $70 Million of Convertible Senior Notes Due 2021
Business Wire - Wed Oct 08, 3:01PM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it intends to offer, subject to market and other considerations, $70,000,000 aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement under the Securities Act of 1933, as amended (the "Securities Act" . Anacor also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $7,000,000 aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. In addition, certain funds affiliated with Venrock Associates (the "Venrock Funds" , one of Anacor's affiliates, have indicated an interest in purchasing $12.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Venrock Notes" in a concurrent private placement under the Securities Act. The Venrock Notes are expected to be sold at the same price, and constitute part of the same series, as the Convertible Notes. The Venrock Funds' indication of interest is not a binding agreement or commitment to purchase the Venrock Notes. ANAC: 33.86 (-0.82)
Insider Trading Alert - NDAQ, ANAC And RNR Traded By Insiders
at The Street - Fri Oct 03, 10:15AM CDT
Stocks with insider trader activity include NDAQ, ANAC and RNR
RNR: 96.64 (-0.77), ANAC: 33.86 (-0.82), NDAQ: 46.11 (-0.86)
Anacor's Kerydin Launched in the US for Onychomycosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:05PM CDT
Anacor Pharmaceuticals, Inc.'s (ANAC) Kerydin has been launched in the U.S. by partner Sandoz Inc., a Novartis company.
ANAC: 33.86 (-0.82), SNY: 45.16 (-1.05), REGN: 416.44 (-7.91), NVS: 93.52 (-0.82)
Anacor Pharmaceuticals unveils antifungal drug KERYDIN (tavaborole) Topical Solution, 5% in the US
M2 - Tue Sep 23, 4:47AM CDT
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) Monday reported the US launch of its US Food and Drug Administration approved drug KERYDINTM (tavaborole) topical solution, 5%.
ANAC: 33.86 (-0.82)
